And, yeah, drug development is high risk. In other news, the sky is still blue.

Type 1 diabetes is still a pretty big market even if you had a one shot cure. There are hundreds of thousands of type 1 diabetics. If they pay a thousand dollars each (a steal at that price), that's hundreds of millions of dollars. For comparison, there are a few thousand people with CML, but that didn't stop Gleevec from being developed for it (it's very expensive).